AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31653221
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and subsequent long-term oral tranexamic acid (TXA)
Trial: 31653221
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral 1 g from POD 1 to POD 14)
Trial: 29374249
Drug: Monthly vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly vitamin D3 50,000 IU orally monthly plus three placebo tablets 3-monthly
Trial: 29374249
Drug: 3-monthly vitamin
RxNorm normalized name: Vitamin K 3
DrugBank: Menadione (DB00170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-monthly vitamin D3 150,000 IU (3 × 50,000 IU tablets) 3-monthly and placebo orally monthly
Trial: 10840005
Drug: Platelet glycoprotein
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin (eptifibatide) Therapy
Trial: 1609767
Drug: Olestra (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra (20 g fat replacement)
Trial: 1609767
Drug: Olestra (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra (0 g fat replacement)
Trial: 31926554
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - TFLM protected by an autogenous tissue 'pad' from the anterior capsule of the joint.
Trial: 30017831
Drug: Nedaplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin (80 mg/m2) plus Docetaxel (75 mg/m2)
Trial: 30017831
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2) plus Docetaxel (75 mg/m2)
Trial: 21629990
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg q2w) plus Cetuximab (400/250 mg/m(2) initial/weekly) with Gemcitabine (1000 mg/m(2) weekly × 3 of 4 weeks)
Trial: 21629990
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg q2w) plus Cetuximab (400/250 mg/m(2) initial/weekly) without Gemcitabine
Trial: 20860915
Drug: Risperidone 1
RxNorm normalized name: risperidone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1 mg Mouth dissolving tablet, Ranbaxy (test product)
Trial: 20860915
Drug: Risperdal 1
RxNorm normalized name: Risperdal 1mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperdal 1 mg Quicklet (reference product)
Trial: 10924844
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day, n=15)
Trial: 8199723
Drug: Metoprolol 50-200
RxNorm normalized name: metoprolol tartrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50-200 mg daily
Trial: 8199723
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Felodipine and Metoprolol
Trial: 3328329
Drug: Chlorproguanil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorproguanil (20 mg base weekly)
Trial: 3328329
Drug: Chloroquine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (200 mg base weekly)
Trial: 31699660
Drug: Rivaroxaban (20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (20-mg equivalent dose, bodyweight-adjusted)
Trial: 31699660
Drug: Standard anticoagulants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulants (heparin or switched to vitamin K antagonist)
Trial: 25312637
Drug: Bivalirudin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin monotherapy
Trial: 15531680
Drug: MM supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MM supplements (vitamins A, B complex, C, D, E, and K and iron, zinc, and magnesium; 6 d/wk for 12 wk)
Trial: 11172190
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (100 U) after initial placebo treatment
Trial: 23706
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dimethpyrindene (0.1 mg/kg b.w.) and cimetidine (10 mg/kg b.w.)
Trial: 25473216
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheet
Trial: 29798375
Drug: Post-auricular subperiosteal
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-auricular subperiosteal injection of methylprednisolone (40 mg/ml)
Trial: 14555500
Drug: Fulvestrant (FVT)
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant (FVT) 250 mg i.m. monthly
Trial: 14555500
Drug: Anastrozole (ANZ)
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole (ANZ) 1 mg p.o. daily
Trial: 1978871
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled bronchodilator treatment (fenoterol)
Trial: 6772381
Drug: Tocainide (17.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide (17.7 +/- 4.9 mg/kg/day)
Trial: 17956584
Drug: 10% IVIg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% IVIg ready‐to‐use solution
Trial: 17956584
Drug: 6% IVIg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% IVIg lyophilized solution
Trial: 10217585
Drug: Calcitriol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (1.0 microg) coadministered with influenza vaccine
Trial: 7574828
Drug: Sunscreen plus
RxNorm normalized name: Sunmark Sunscreen Plus E and Aloe SPF 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunscreen plus UVB (SPF 29 sunscreen containing octyl methoxycinnamate, oxybenzone, and octyl salicylate) followed by three minimal erythema doses of UVB irradiation.
Trial: 7574828
Drug: UVB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB group (three minimal erythema doses of UVB irradiation without sunscreen).
Trial: 2710641
Drug: Carbamazepine divitabs
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine divitabs (sustained-release formulation)
Trial: 2710641
Drug: Carbamazepine normal
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine normal formulation (ordinary tablets)
Trial: 7015139
Drug: Tamoxifen combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen combined with L‐phenylalanine mustard and 5‐fluorouracil
Trial: 31522806
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine with 85% efficacy
Trial: 31522806
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine with 50% efficacy
Trial: 31522806
Drug: Vaccine-related social
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine-related social concerns
Trial: 7653319
Drug: Behavioral marital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral marital therapy (BMT) with relapse prevention (RP)
Trial: 7653319
Drug: Behavioral marital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral marital therapy (BMT) without relapse prevention (RP)
Trial: 20837791
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injection
Trial: 8091463
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) at 1 g per kg per day for 2 consecutive days each week for 4 weeks
Trial: 8091463
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline placebo administered according to the same schedule as IVIG
Trial: 29759857
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of IV‐TXA at 3‐hour intervals (group C)
Trial: 21146270
Drug: eGFR ≥75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR ≥75 mL/min/1.73 m(2)
Trial: 21146270
Drug: eGFR <30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <30 mL/min/1.73 m(2) and dipstick-positive proteinuria
Trial: 16479736
Drug: Personalized asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalized asthma desensitization (previously specific immunotherapy, SIT)
Trial: 16479736
Drug: Usual medications
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medications (control group)
Trial: 12207596
Drug: Intermittent fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent fluticasone propionate (FP) cream 0.05% (twice per week)
Trial: 8567611
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy adapted for sexually abused preschool children (CBT-SAP)
Trial: 9291724
Drug: Nondirective supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondirective supportive therapy (NST)
Trial: 1858672
Drug: Bepridil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (200 to 400 mg/day)
Trial: 22251061
Drug: Traditional liquid
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional liquid spray pump (Spray)
Trial: 16438474
Drug: Ropinirole (0.25-4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.25-4.0 mg once daily, 1 to 3 hours before bedtime)
Trial: 1408294
Drug: Morphine by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine by PKPCA
Trial: 1785361
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (low-salt diet 70 to 90 mEq of Na per day, stopping diuretics and laxatives, elastic stockings) + carbidopa/levodopa 25/100 (3 tabs/day) + captopril 6.25 mg q 8 h
Trial: 30975143
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg, twice daily for 12 months)
Trial: 28205322
Drug: Exenatide QWS-AI
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide QWS-AI 2.0 mg
Trial: 21372444
Drug: LAC2E (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + clarithromycin 200 mg bid + ecabet sodium 2 g bid for 1 week)
Trial: 21372444
Drug: LA2E (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA2E (lansoprazole 30 mg bid + amoxicillin 750 mg bid + ecabet sodium 2 g bid for 2 weeks)
Trial: 19141090
Drug: Adjunctive devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive devices during percutaneous coronary intervention (PCI)
Trial: 14979943
Drug: One per
RxNorm normalized name: Just One Per Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One per cent silver nitrate gel
Trial: 14979943
Drug: 0.1 per
RxNorm normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 per cent silver nitrate gel
Trial: 10929023
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplantation (ASCT) after high-dose chemotherapy (BEAM regimen)
Trial: 9382536
Drug: Neoadjuvant intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant intra-arterial infusion chemotherapy (Epirubicin on Days 1, 3, 5, 7 + MPA 1,200 mg)
Trial: 9382536
Drug: Adjuvant intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intravenous chemotherapy
Trial: 8452102
Drug: Toremifene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (20 to 200 mg/day)
Trial: 31874283
Drug: Tiotropium Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat 5 μg
Trial: 31874283
Drug: Tiotropium Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Respimat 2.5 μg
Trial: 12063159
Drug: Sertraline alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline alone (50-200 mg)
Trial: 16263177
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus IPT
Trial: 23983248
Drug: Brain natriuretic
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain natriuretic peptide >100 pg/mL
Trial: 12628864
Drug: Nasal CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal CPAP with oral device
Trial: 9118652
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion at 10 micrograms/kg/min
Trial: 7681656
Drug: Poly(I):poly(C12U) 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly(I):poly(C12U) 600 mg
Trial: 7681656
Drug: Poly(I):poly(C12U) 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly(I):poly(C12U) 200 mg
Trial: 25444805
Drug: 2009-H1N1 vaccine
RxNorm normalized name: influenza A virus A/California/7/2009 (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009-H1N1 vaccine + Placebo
Trial: 25444805
Drug: H1N1 vaccine
RxNorm normalized name: Influenza H1N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1N1 vaccine + Placebo + IIV3
Trial: 3914368
Drug: Fluocinonide ointment
RxNorm normalized name: Fluocinonide Ointment
DrugBank: Fluocinonide (DB01047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinonide ointment 0.05%
Trial: 11239618
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 microg vaginally, administered at home 24 hours after mifepristone.
Trial: 11239618
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 microg vaginally, administered at home 48 hours after mifepristone.
Trial: 11239618
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 microg vaginally, administered at home 72 hours after mifepristone.
Trial: 1627763
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta administered subcutaneously (s.c.) with two doses per week
Trial: 1627763
Drug: Subcutaneous dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dosing two or three times a week
Trial: 31544230
Drug: Two consecutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two consecutive doses of 24 mg intravenous dexamethasone (DXM)
Trial: 28525303
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with diode laser 830 nm
Trial: 26019694
Drug: Garlic (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic (900 mg powdered garlic)
Trial: 24316697
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the same dosage as Bromelain
Trial: 19720922
Drug: Plerixafor (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (240 microg/kg) plus G-CSF (10 microg/kg)
Trial: 19720922
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus G-CSF (10 microg/kg)
Trial: 8326972
Drug: Pilocarpine 10
RxNorm normalized name: pilocarpine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine 10 mg orally three times a day for 12 weeks
Trial: 3551671
Drug: Saline nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline nebulization (2 ml saline t.i.d.)
Trial: 3551671
Drug: Bromhexine nebulization
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine nebulization (2 ml bromhexine, 2 mg/ml t.i.d.)
Trial: 21268547
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg (E250)
Trial: 21268547
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg (E500)
Trial: 21268547
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg (M)
Trial: 21268547
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg (Z)
Trial: 12576259
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg per day
Trial: 10738641
Drug: Vincamine reference
RxNorm normalized name: vincamine
DrugBank: Vincamine (DB13374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincamine reference product (60 mg single dose)
Trial: 8646829
Drug: Twice-a-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day regimen
Trial: 8646829
Drug: Doses taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses taken at prescribed intervals
Trial: 2056895
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment at 0.0 W.cm‐2
Trial: 2056895
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment at 1.5 W.cm‐2, pulsed 50%
Trial: 2056895
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment at 1.5 W.cm‐2, continuous
Trial: 6405876
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acebutolol combined with 12.5 mg hydrochlorothiazide
Trial: 6405876
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of hydrochlorothiazide
Trial: 26929219
Drug: Tocilizumab infusions
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab infusions at 4-week intervals (3 infusions total) followed by oral prednisone from weeks 12 to 24 (0.15 mg/kg if PMR-AS ≤10 and 0.30 mg/kg otherwise)
Trial: 26929219
Drug: Tocilizumab infusions
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab infusions
Trial: 23019949
Drug: Jing'an Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jing'an Oral Liquid (JOL)
Trial: 17935230
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (2 mg/kg/day from day 7 to day 21 and 1 mg/kg/day from day 22 to day 28)
Trial: 11895960
Drug: Peru-15 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peru-15 vaccine (2 x 10^8 CFU)
Trial: 7637364
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy plus dipyridamole (225 to 400 mg per day)
Trial: 17158523
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy alone
Trial: 7637364
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy plus dipyridamole
Trial: 6218101
Drug: antibiotics selected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotics selected on the basis of bacteriological results (Regimen D)
Trial: 16941337
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment (HAART initiated within 2 weeks of seroconversion)
Trial: 16941337
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (HAART initiated between 2 weeks and 6 months after seroconversion)
Trial: 27498099
Drug: Monthly module
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly module group
Trial: 27498099
Drug: Weekly module
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly module group
Trial: 19940233
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg plus Rabeprazole 10 mg
Trial: 19940233
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg (once daily)
Trial: 12576938
Drug: Filgrastim (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (300 microg/day) administered as a 30-min intravenous infusion for 5 days or until white blood cell count reached >75.0 x 10(9) cells/L